摘要
目的 观察达格列净联合缬沙坦治疗2型糖尿病肾病患者的临床效果。方法 70例2型糖尿病肾病患者,根据治疗意愿分为对照组及观察组,每组35例。两组患者均予以低脂低盐、糖尿病饮食、适当锻炼运动及降血压、降血糖、纠正脂质生理代谢过程紊乱、抗血小板聚集及改善微循环状态等综合措施治疗,对照组予以缬沙坦片口服治疗,观察组在对照组基础上予以达格列净片口服治疗。比较两组患者治疗前后血糖相关指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]及肾功能相关指标[尿素氮(BUN)、尿微量白蛋白(UmAlb)、24 h尿蛋白定量(U-PRO)]。结果 治疗前,两组患者FPG、2 h PG及HbA1c水平比较差异无统计学意义(P>0.05);治疗后,两组患者FPG、2 h PG及HbA1c水平均较本组治疗前下降,且观察组患者FPG、2 h PG及HbA1c水平分别为(6.80±0.93)mmol/L、(8.21±1.56)mmol/L、(5.44±0.57)%,均低于对照组的(7.72±1.14)mmol/L、(10.01±1.82)mmol/L、(6.72±0.69)%,差异有统计学意义(P<0.05)。治疗前,两组患者BUN、UmAlb及U-PRO水平比较差异无统计学意义(P>0.05);治疗后,两组患者BUN、UmAlb及U-PRO水平均较本组治疗前下降,且观察组患者BUN、UmAlb及U-PRO水平分别为(8.40±0.87)mmol/L、(28.95±8.51)mg/L、(106.71±15.19)mg/24 h,均低于对照组的(10.89±1.41)mmol/L、(37.71±9.67)mg/L、(121.96±17.52)mg/24 h,差异有统计学意义(P<0.05)。结论 与单一采用缬沙坦治疗比较,达格列净联合缬沙坦可明显改善2型糖尿病肾病患者血糖指标及肾功能指标,值得临床广泛应用。
Objective To observe the clinical effect of dapagliflozin combined with valsartan in the treatment of type 2 diabetic nephropathy.Methods A total of 70 patients with type 2 diabetic nephropathy were divided into control group and observation group according to their willingness to treat,with 35 cases in each group.Both groups were treated with comprehensive measures such as low-fat and low-salt,diabetic diet,appropriate exercise,lowering blood pressure,lowering blood glucose,correcting the disorder of lipid physiological metabolism,anti-platelet aggregation and improving microcirculation state.On this basis,the control group was treated with valsartan,and the observation group was treated with dapagliflozin tablets orally on the basis of the control group.Both groups were compared in terms of blood glucose-related indicators[fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),glycosylated hemoglobin(HbA1c)]and renal function-related indicators[blood urea nitrogen(BUN),urinary microalbumin(UmAlb),urinary protein(U-PRO)]before and after treatment.Results Before treatment,there was no statistically significant difference in the levels of FPG,2 h PG and HbA1c between the two groups(P>0.05).After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were decreased compared with those before treatment in this group,and the levels of FPG,2 h PG and HbA1c in the observation group were(6.80±0.93)mmol/L,(8.21±1.56)mmol/L and(5.44±0.57)%,which were lower than(7.72±1.14)mmol/L,(10.01±1.82)mmol/L and(6.72±0.69)%in the control group.All the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of BUN,UmAlb and U-PRO between the two groups(P>0.05).After treatment,the levels of BUN,UmAlb and U-PRO in the two groups were decreased compared with those before treatment in this group,and the levels of BUN,UmAlb and U-PRO in the observation group were(8.40±0.87)mmol/L,(28.95±8.51)mg/L and(106.71±15.19)mg/24 h,which were lower than
作者
陈荣
CHEN Rong(General Clinic,the Community Health Service Center of Jiyuqiao Street of Wuchang District,Wuhan 430060,China)
出处
《中国现代药物应用》
2022年第14期33-36,共4页
Chinese Journal of Modern Drug Application
关键词
达格列净
缬沙坦
糖尿病肾病
效果
Dapagliflozin
Valsartan
Diabetic nephropathy
Effect
